QUAN THAI: Open Payments
NPI 1700029105 · STANFORD, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$594 in 20 payments from 12 companies in 2025. Trend: 2023 $378 · 2024 $348 · 2025 $594
Food & beverage: $594
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 1 | $128 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Daiichi Sankyo Inc. | 3 | $64 |
| Merck Sharp & Dohme LLC | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $54 |
| Novartis Pharmaceuticals Corporation | 2 | $49 |
| Janssen Biotech, Inc. | 1 | $39 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| ABBVIE INC. | 1 | $24 |
Products named: OPDIVO, CALQUENCE, OJJAARA, Vanflyta, Fabhalta, TALVEY, KEYTRUDA, ELZONRIS.
Industry payments across CA — which companies pay providers there.
